Navigation Links
ERT to Present at the Citi 2011 Global Health Care Conference on November 15, 2011
Date:11/7/2011

PHILADELPHIA, Nov. 7, 2011 /PRNewswire/ -- ERT (Nasdaq: ERT), announced today that Dr. Jeffrey S. Litwin, the Company's President and CEO is scheduled to present at the Citi 2011 Global Health Care Conference at 1:00PM PST on Nov. 15, 2011 in Las Vegas.

Interested parties may access the presentation by visiting the Company's corporate website at http://www.ert.com. The webcast may also be accessed at http://www.veracast.com/webcasts/citigroup/smidcap2011/98108111.cfm. The webcast will be available via replay for 90 days.

About ERTERT (www.ert.com) is a global technology-driven provider of clinical services and customizable medical devices to biopharmaceutical and healthcare organizations. It is the market leader for centralized cardiac safety and respiratory efficacy services in drug development and also collects, analyzes and distributes electronic Patient Reported Outcomes (ePRO) in multiple modalities across all phases of clinical research.

Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties, which could cause actual results to differ materially from those expressed or implied from such statements. These risks and uncertainties include, without limitation, the Company's ability to obtain new contracts, variability in size, scope, and duration of projects, integration of acquisitions, competitive factors, technological development, market demand, and other factors described in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of n
'/>"/>

SOURCE ERT
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Onyx Pharmaceuticals Announces Data Presentations Highlighting Carfilzomib at 53rd American Society of Hematology Annual Meeting
2. Cantel Medical Corp. to Present at the Stephens Inc. Fall Investment Conference
3. Abaxis, Inc. to Present at Sidoti & Companys New York II Emerging Growth Institutional Investor Forum
4. Caliper CEO Kevin Hrusovsky Presented Vision for Revolutionizing Medicine
5. Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheims Two Investigational HCV Direct Acting Antivirals Presented at AASLD
6. Vermillion to Present at Stephens Fall Investment Conference on November 16, 2011
7. Pharmacyclics Reports Fiscal 2012 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 53rd American Society of Hematology Annual Meeting
8. PAREXEL International to Present at Lazard Capital Markets Healthcare Conference and Citi Small/Mid Cap Conference
9. Tibotec to Present Final Safety and Efficacy Results From Phase 2b PILLAR Study of Once-Daily TMC435 in Late-Breaker at AASLD
10. Volcano Corporation Announces Upcoming Presentation of Late-Breaking Clinical Trial Results and FFR Product Launch at TCT 2011
11. HeartWare to Present at the Credit Suisse 2011 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... LONDON , August 28, 2015 ... seamlessly connects people, technologies and care protoc ... improving outcomes and the cost of healthcare delivery   ... today announced its presence at  ESC Congress 2015 , where the ... A.I. , EchoNavigator and IntelliSpace Cardiovascular, that connect people and ...
(Date:8/27/2015)...  A recent study by Feucht et al, ... Arthrosurface HemiCAP® Wave implant, which is based on ... implant for isolated patellofemoral disease. While both implant ... scores, none of the patients in the "inlay" ... of the patients in the "onlay" group, showed ...
(Date:8/27/2015)... , Aug. 27, 2015 ieCrowd™ ... in the commercial development of the company,s supplemental ... Smart Oxygen device, being developed by ieCrowd,s subsidiary ... a patient,s changing demand for oxygen based on ... 510 (k) submission for the Smart Oxygen device ...
Breaking Medicine Technology:Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 4
... the global leader in technology support and BPO services ... today the opening of its new Global Operations Center ... city of Dalian, will specialize in providing services in ... sponsors and clinical research organizations. With dramatic ...
... ARBOR, Mich., April 7, 2011 Adeona Pharmaceuticals, Inc. (AMEX: ... serious central nervous system diseases, announced today that it has ... its common stock at approximately $2.0725 per share to a ... million in gross proceeds. The investor will also receive warrants ...
Cached Medicine Technology:C3i Opens Asia Language Center in Dalian, China 2Adeona to Raise $3.5 Million in Registered Direct Offering 2Adeona to Raise $3.5 Million in Registered Direct Offering 3
(Date:8/29/2015)... ... August 29, 2015 , ... Vascular ... market and sell Arterosil and Arterosil HP, and that all claims and counterclaims ... Vascular Health Sciences, LLC (VHS) in the United States District Court for the ...
(Date:8/28/2015)... ... 2015 , ... The Kentucky State Department of Workforce Investment Commissioner Beth Kuhn ... applying for, they are unable to pass the initial drug test and therefore unable ... in order to be able to hire long-term, skilled talent. (1) Will Wesch, Director ...
(Date:8/28/2015)... ... , ... As reported by Medical Daily on August 22 , Cellfina, ... last for two years, the longest of any cellulite reduction system currently on the ... long-lasting, effective solution for their cellulite, according to Dr. Robert Weiss, director of the ...
(Date:8/28/2015)... ... , ... “ Frequentz ” was featured on NewsWatch as part of its ... market for iOS, Android, and Windows. Joe Toohey, the host of AppWatch and technology ... to track product movement from beginning to end. , Businesses benefit greatly from having ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... three-year accreditation for its adolescent residential, counseling, day treatment and intensive family based ... meets international standards for quality and its pursuit of excellence. As a nonprofit ...
Breaking Medicine News(10 mins):Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Track Product Movement from Beginning to End with Frequentz 2Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2
... diet/nutrition as leading issue; exercise, physical changes, ... drug use also rank ... report from,the C.S. Mott Children,s Hospital National Poll on Children,s Health ... with kids ages 11 to 17 during routine check-ups. The topics ...
... Davis Collaboration, RANCHO CORDOVA, Calif., Feb. 6 ... supplier of innovative products and,services that process and ... injury, today announced a regenerative medicine initiative in ... wholly-owned subsidiary, Vantus, Inc., a,veterinary stem cell laboratory ...
... first step toward personalized medicine, experts say , , WEDNESDAY, Feb. ... blood test could help a small minority of HIV patients ... can sometimes cause serious side effects. , The test detects ... a patient,s genetic makeup is linked to poor reactions to ...
... multiple risk factors at once, , , WEDNESDAY, Feb. 6 (HealthDay ... showing signs of some kidney damage may be able to ... factors at once. , That,s the conclusion of a ... the New England Journal of Medicine , that found ...
... Burnham Institute for Medical Research (Burnham Institute) have provided ... a suppressor role in skin cancer development. ATF2 ... the first step in the translation of genetic code, ... and ionizing radiation. This function of ATF2 in ...
... has announced the names of the recipients of its annual ... Inder Verma is the prize recipient for biomedical science; the ... The Vilcek Foundation Prizes are awarded annually to foreign-born individuals ... , In explaining the motivation for the awards, Dr. ...
Cached Medicine News:Health News:Parents Identify Health Topics They Want Doctors to Discuss with Kids - New Research for University of Michigan Conducted by Knowledge Networks 2Health News:Thermogenesis Announces New Initiative to Address Veterinary Regenerative Medicine 2Health News:Thermogenesis Announces New Initiative to Address Veterinary Regenerative Medicine 3Health News:Thermogenesis Announces New Initiative to Address Veterinary Regenerative Medicine 4Health News:Test Detects Sensitivity to HIV Drug 2Health News:Aggressive Diabetes Therapy Lowers Death Risk, Study Finds 2Health News:Aggressive Diabetes Therapy Lowers Death Risk, Study Finds 3Health News:Gene found to play a suppressor role in skin cancer development 2Health News:Dr. Inder Verma named recipient of 2008 Vilcek Prize in biomedical science 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: